{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:19:13Z","timestamp":1773800353672,"version":"3.50.1"},"reference-count":37,"publisher":"Japanese Society of Veterinary Science","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Veterinary Medical Science","J. Vet. Med. Sci."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1292\/jvms.15-0625","type":"journal-article","created":{"date-parts":[[2015,12,20]],"date-time":"2015-12-20T22:08:45Z","timestamp":1450649325000},"page":"649-656","source":"Crossref","is-referenced-by-count":9,"title":["Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma"],"prefix":"10.1292","volume":"78","author":[{"given":"Mami","family":"ADACHI","sequence":"first","affiliation":[{"name":"Laboratory of Advanced Veterinary Medicine, Department of Veterinary Clinical Sciences, Hokkaido University, Hokkaido 060\u20130818, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"HOSHINO","sequence":"additional","affiliation":[{"name":"Veterinary Teaching Hospital, Hokkaido University, Hokkaido 060\u20130818, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"IZUMI","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Veterinary Medicine, Department of Veterinary Clinical Sciences, Hokkaido University, Hokkaido 060\u20130818, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"TAKAGI","sequence":"additional","affiliation":[{"name":"Veterinary Teaching Hospital, Hokkaido University, Hokkaido 060\u20130818, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Amagai, Y., Tanaka, A., Matsuda, A., Oida, K., Jung, K. and Matsuda, H. 2013. The phosphoinositide 3-kinase pathway is crucial for the growth of canine mast cell tumors. <i>J. Vet. Med. Sci.<\/i> 75: 791\u2013794.","DOI":"10.1292\/jvms.12-0540"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Andersen, N. J., Nickoloff, B. J., Dykema, K. J., Boguslawski, E. A., Krivochenitser, R. I., Froman, R. E., Dawes, M. J., Baker, L. H., Thomas, D. G., Kamstock, D. A., Kitchell, B. E., Furge, K. A. and Duesbery, N. S. 2013. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. <i>Mol. Cancer Ther.<\/i> 12: 1701\u20131714.","DOI":"10.1158\/1535-7163.MCT-12-0893"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Arbiser, J. L., Weiss, S. W., Arbiser, Z. K., Bravo, F., Govindajaran, B., Caceres-Rios, H., Cotsonis, G., Recavarren, S., Swerlick, R. A. and Cohen, C. 2001. Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. <i>J. Am. Acad. Dermatol.<\/i> 44: 193\u2013197.","DOI":"10.1067\/mjd.2000.111632"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Baker, A. F., Dragovich, T., Ihle, N. T., Williams, R., Fenoglio-Preiser, C. and Powis, G. 2005. Stability of phosphoprotein as a biological marker of tumor signaling. <i>Clin. Cancer Res.<\/i> 11: 4338\u20134340.","DOI":"10.1158\/1078-0432.CCR-05-0422"},{"key":"5","unstructured":"5. Bastianello, S. S. 1983. A survey on neoplasia in domestic species over a 40-year period from 1935 to 1974 in the Republic of South Africa. VI. Tumours occurring in dogs. <i>Onderstepoort J. Vet. Res.<\/i> 50: 199\u2013220."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Brown, N. O., Patnaik, A. K. and MacEwen, E. G. 1985. Canine hemangiosarcoma: retrospective analysis of 104 cases. <i>J. Am. Vet. Med. Assoc.<\/i> 186: 56\u201358.","DOI":"10.2460\/javma.1985.186.01.56"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Brown, R. J., Newman, S. J., Durtschi, D. C. and Leblanc, A. K. 2012. Expression of PDGFR-\u03b2 and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry. <i>Vet. Comp. Oncol.<\/i> 10: 74\u201379.","DOI":"10.1111\/j.1476-5829.2011.00286.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M. and Vogt, P. K. 1997. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. <i>Science<\/i> 276: 1848\u20131850.","DOI":"10.1126\/science.276.5320.1848"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dickerson, E. B., Thomas, R., Fosmire, S. P., Lamerato-Kozicki, A. R., Bianco, S. R., Wojcieszyn, J. W., Breen, M., Helfand, S. C. and Modiano, J. F. 2005. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. <i>Vet. Pathol.<\/i> 42: 618\u2013632.","DOI":"10.1354\/vp.42-5-618"},{"key":"10","unstructured":"10. Dorn, C. R., Taylor, D. O., Schneider, R., Hibbard, H. H. and Klauber, M. R. 1968. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. <i>J. Natl. Cancer Inst.<\/i> 40: 307\u2013318."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Faivre, S., Kroemer, G. and Raymond, E. 2006. Current development of mTOR inhibitors as anticancer agents. <i>Nat. Rev. Drug Discov.<\/i> 5: 671\u2013688.","DOI":"10.1038\/nrd2062"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gordon, I. K., Ye, F. and Kent, M. S. 2008. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. <i>Am. J. Vet. Res.<\/i> 69: 1079\u20131084.","DOI":"10.2460\/ajvr.69.8.1079"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hammer, A. S., Couto, C. G., Filppi, J., Getzy, D. and Shank, K. 1991. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. <i>J. Vet. Intern. Med.<\/i> 5: 160\u2013166.","DOI":"10.1111\/j.1939-1676.1991.tb00943.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Huang, Y. N., Ho, Y. J., Lai, C. C., Chiu, C. T. and Wang, J. Y. 2015. 1,25-Dihydroxyvitamin D3 attenuates endotoxin-induced production of inflammatory mediators by inhibiting MAPK activation in primary cortical neuron-glia cultures. <i>J. Neuroinflammation<\/i> 12: 147\u2013158.","DOI":"10.1186\/s12974-015-0370-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jiang, B. H. and Liu, L. Z. 2008. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. <i>Drug Resist. Updat.<\/i> 11: 63\u201376.","DOI":"10.1016\/j.drup.2008.03.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Jin, M., Takahashi, M., Moto, M., Muguruma, M., Ito, K., Watanabe, K., Kenmochi, Y., Kono, T., Hasumi, K. and Mitsumori, K. 2007. Carcinogenic susceptibility of rasH2 mice to troglitazone. <i>Arch. Toxicol.<\/i> 81: 883\u2013894.","DOI":"10.1007\/s00204-007-0218-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jin, M., Matsumoto, S., Dewa, Y., Nishimura, J., Saekusa, Y., Hasumi, K. and Mitsumori, K. 2008. Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. <i>Arch. Toxicol.<\/i> 82: 771\u2013777.","DOI":"10.1007\/s00204-008-0293-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Jones, R. J., Boyce, T., Fennell, M., Jacobs, V., Pinto, F., Duffield, E., Clack, G., Green, T., Kelly, J. and Robertson, J. 2008. The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. <i>Cancer Chemother. Pharmacol.<\/i> 61: 23\u201332.","DOI":"10.1007\/s00280-007-0440-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kent, M. S., Collins, C. J. and Ye, F. 2009. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines. <i>Am. J. Vet. Res.<\/i> 70: 263\u2013269.","DOI":"10.2460\/ajvr.70.2.263"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lahat, G., Dhuka, A. R., Hallevi, H., Xiao, L., Zou, C., Smith, K. D., Phung, T. L., Pollock, R. E., Benjamin, R., Hunt, K. K., Lazar, A. J. and Lev, D. 2010. Angiosarcoma: clinical and molecular insights. <i>Ann. Surg.<\/i> 251: 1098\u20131106.","DOI":"10.1097\/SLA.0b013e3181dbb75a"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lana, S., U\u2019ren, L., Plaza, S., Elmslie, R., Gustafson, D., Morley, P. and Dow, S. 2007. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. <i>J. Vet. Intern. Med.<\/i> 21: 764\u2013769.","DOI":"10.1111\/j.1939-1676.2007.tb03019.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lee, Y. J., Karl, D. L., Maduekwe, U. N., Rothrock, C., Ryeom, S., D\u2019Amore, P. A. and Yoon, S. S. 2010. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. <i>Cancer Res.<\/i> 70: 8357\u20138367.","DOI":"10.1158\/0008-5472.CAN-10-1138"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Leow-Dyke, S., Allen, C., Denes, A., Nilsson, O., Maysami, S., Bowie, A. G., Rothwell, N. J. and Pinteaux, E. 2012. Neuronal Toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro. <i>J. Neuroinflammation<\/i> 9: 230\u2013240.","DOI":"10.1186\/1742-2094-9-230"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Liu, L., Kakiuchi-Kiyota, S., Arnold, L. L., Johansson, S. L., Wert, D. and Cohen, S. M. 2013. Pathogenesis of human hemangiosarcomas and hemangiomas. <i>Hum. Pathol.<\/i> 44: 2302\u20132311.","DOI":"10.1016\/j.humpath.2013.05.012"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. MacVean, D. W., Monlux, A. W., Anderson, P. S. Jr., Silberg, S. L. and Roszel, J. F. 1978. Frequency of canine and feline tumors in a defined population. <i>Vet. Pathol.<\/i> 15: 700\u2013715.","DOI":"10.1177\/030098587801500602"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Matsumura, I., Mizuki, M. and Kanakura, Y. 2008. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. <i>Cancer Sci.<\/i> 99: 479\u2013485.","DOI":"10.1111\/j.1349-7006.2007.00717.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Murai, A., Asa, S. A., Kodama, A., Hirata, A., Yanai, T. and Sakai, H. 2012. Constitutive phosphorylation of the mTORC2\/Akt\/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. <i>BMC Vet. Res.<\/i> 8: 128\u2013141.","DOI":"10.1186\/1746-6148-8-128"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Murai, A., Abou Asa, S., Kodama, A., Sakai, H., Hirata, A. and Yanai, T. 2012. Immunohistochemical analysis of the Akt\/mTOR\/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas. <i>J. Comp. Pathol.<\/i> 147: 430\u2013440.","DOI":"10.1016\/j.jcpa.2012.05.002"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ogilvie, G. K., Powers, B. E., Mallinckrodt, C. H. and Withrow, S. J. 1996. Surgery and doxorubicin in dogs with hemangiosarcoma. <i>J. Vet. Intern. Med.<\/i> 10: 379\u2013384.","DOI":"10.1111\/j.1939-1676.1996.tb02085.x"},{"key":"30","unstructured":"30. Prymak, C., McKee, L. J., Goldschmidt, M. H. and Glickman, L. T. 1988. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). <i>J. Am. Vet. Med. Assoc.<\/i> 193: 706\u2013712."},{"key":"31","unstructured":"31. Ravandi, F., Talpaz, M. and Estrov, Z. 2003. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. <i>Clin. Cancer Res.<\/i> 9: 535\u2013550."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Sailasuta, A., Ketpun, D., Piyaviriyakul, P., Theerawatanasirikul, S., Theewasutrakul, P. and Rungsipipat, A. 2014. The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells. <i>Vet. Med. Int.<\/i> 2014: 787498.","DOI":"10.1155\/2014\/787498"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sorenmo, K. U., Baez, J. L., Clifford, C. A., Mauldin, E., Overley, B., Skorupski, K., Bachman, R., Samluk, M. and Shofer, F. 2004. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. <i>J. Vet. Intern. Med.<\/i> 18: 209\u2013213.","DOI":"10.1111\/j.1939-1676.2004.tb00162.x"},{"key":"34","unstructured":"34. Spangler, W. L. and Culbertson, M. R. 1992. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985\u20131989). <i>J. Am. Vet. Med. Assoc.<\/i> 200: 829\u2013834."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Spangler, W. L. and Kass, P. H. 1997. Pathologic factors affecting postsplenectomy survival in dogs. <i>J. Vet. Intern. Med.<\/i> 11: 166\u2013171.","DOI":"10.1111\/j.1939-1676.1997.tb00085.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Wendelburg, K. M., Price, L. L., Burgess, K. E., Lyons, J. A., Lew, F. H. and Berg, J. 2015. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001\u20132012). <i>J. Am. Vet. Med. Assoc.<\/i> 247: 393\u2013403.","DOI":"10.2460\/javma.247.4.393"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Wood, C. A., Moore, A. S., Gliatto, J. M., Ablin, L. A., Berg, R. J. and Rand, W. M. 1998. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). <i>J. Am. Anim. Hosp. Assoc.<\/i> 34: 417\u2013421.","DOI":"10.5326\/15473317-34-5-417"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/78\/4\/78_15-0625\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T21:46:32Z","timestamp":1748727992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/78\/4\/78_15-0625\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.15-0625","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}